A systematic analysis of FDA-approved anticancer drugs
Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology 2017, 11: 87. PMID: 28984210, PMCID: PMC5629554, DOI: 10.1186/s12918-017-0464-7.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsDrug ApprovalHumansMolecular Targeted TherapyNeoplasmsUnited StatesUnited States Food and Drug AdministrationConceptsDrug-cancer associationsAnticancer drugsTarget-based drugsEfficient anticancer drugsTarget-based approachCancer typesNew anticancer drugsNovel anticancer drugsClinical trial studyPharmaceutical researchTrial studyMore cancer typesUS FoodDrug AdministrationCytotoxic drugsPatient treatmentPotential candidateDrug mechanismsDrugsDrug repurposingSystematic investigationAssociationDrug targetsTyrosine kinaseSystematic discovery